Analysis of protease and reverse transcriptase genes of HIV for antiretroviral drug resistance in Jamaican adults

AIDS Research and Human Retroviruses

Volumn 28, Issue 8, 2012, Pages 923-927

  Hamilton, Cindy Leigh C ^a   Eyzaguirre, Lindsay M ^b   Amarakoon, Icolyn I ^a   Figueroa, Peter ^a   Duncan, Jacqueline ^c   Carr, Jean K ^b   Roye, Marcia E ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Ministry of Health   (Jamaica)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD SAMPLING; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; ENZYME ANALYSIS; EPIDEMIOLOGY; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAMAICA; LOW DRUG DOSE; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; PLASMA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; VEIN PUNCTURE; VIRUS GENOME;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; JAMAICA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; RNA, VIRAL;

EID: 84864229093     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0312     Document Type: Article

References (17)

1. Ministry of Health, Jamaica: National HIV/STI Program, Jamaica Country Progress Report to the Secretary General of the United Nations on the United Nations General Assembly Special Session. Reporting period: January 2008-December 2009.
2. Rodríguez-Rosado R, Briones C, and Soriano V: Introduction of HIV drug-resistance testing in clinical practice. AIDS 1999;13:1007-1014.
3. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogensis and therapy. Science 1995;267:483-489.
4. Hirsch MS, Gunthard HF, Richman DD, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008;47:266-285.
5. Nadai Y, Eyzaguirre LM, Sill A, Cleghorn F, Nolte C, Carr JK, et al.: HIV-1 epidemic in the Caribbean is dominated by subtype B. PLoS ONE 2009;4(3):e4814.doi:10.1371/journal. pone.0004814.
6. Heslop OD, Smikle MF, et al.: Human immunodeficiency virus type-1 (HIV-1) subtypes in Jamaica. West Indian Med J 2005;54(5):279.
7. Caron M, Makuwa M, Souquière S, Descamps D, Brun-Vé- zinet F, and Kazanji M: Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistanceassociated mutations in miners in Gabon, Central Africa. AIDS Res Hum Retroviruses 2008;24(9):1225-1228.
8. Dudley J, Kumar S, Nei M, and Tamura K: MEGA4: Molecular evolutionary genetics analysis (MEGA) Software Version 4.0. Mol Biol Evol 2007;24(8):1596-1599.
9. Hammer SM, Eron JJ, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS Society-USA Panel. JAMA 2010;300: 555-570.
10. Sluis-Cremer N: Molecular mechanisms of HIV resistance to nucleoside and nucleotide reverse transcriptase inhibitors. Future HIV Ther 2007;1(2):191-201.
11. Wainberg MA: HIV resistance to nevirapine and other nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2003;34:S2-S7.
12. Minuto JJ and Haubrich R: Etravine: A second-generation NNRTI for treatment-experienced adults with resistance HIV-1 infection. Future HIV Ther 2008;2(6):525-537.
13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL .pdf. Accessed 10 May 2010.
14. Lathouwers E, Meyer SD, Dierynck I, et al.: Virological characterisation of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96- week analysis. Antiviral Ther 2011;16:99-108.
15. Rhee S, Taylor J, Fessel WJ, et al.: HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 2010;54(10):4253-4261.
16. Murillo W, De Rivera IL, Parham L, et al.: Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med 2010;11:95-103.
17. Maglione M, Goetz MB, Zhen Wang Z, et al.: Antiretroviral (ARV) Drug Resistance in the Developing World Evidence eports/Technology Assessments, No. 156. AHRQ Publication No. 07-E014. Rockville, MD: Agency for Healthcare Research nd Quality 2007;1-74.